Abstract 359P
Background
In particular, cancer patients with minor children encounter various problems, including family, parenting, employment, and economic burdens. This study aimed to examine the economic burden among cancer patients with minor children.
Methods
This was a sub-analysis of a cross-sectional web-based survey. Cancer patients with minor children were recruited from an online community and asked to answer a questionnaire.The proportion of subjects experiencing economic burden, and factors associated with economic burden were analyzed.
Results
A total of 368 subjects were eligible [19% male, mean age (SD): 43.0 years (5.8)]. The most common primary cancer site was breast (34%), followed by the colorectal region (12%), and gynecological organs (11%). Among the subjects, 127 (34%) experiencedeconomic burden. Univariate analyses showed that advanced stage (38% in subjects experiencing economic burden vs. 22% in subjects not experiencingeconomic burden, p = 0.002), presence of metastases (51% vs. 35%, p = 0.004), cancer recurrence (24% vs. 14%, p = 0.032), using anti-tumor drugs (47% vs. 33%, p = 0.010), having a full-time job (24% vs. 48%, p < 0.001), change of work situation (76% vs. 44%, p < 0.001), and decrease of income (76% vs. 38%, p < 0.001) were associated with patients experiencingeconomic burden.
Conclusions
The present study showed that advanced stage, anti-tumor treatment, and work situation were associated with economic burden among cancer patients with minor children.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Center.
Funding
Takeda Science Foundation.
Disclosure
K. Kosugi: Honoraria (self): Mundipharma. D. Fujisawa: Honoraria (self): Pfeizer, Mochida, Tanabe-Mitsubishi, Shionogi, Meiji Pharma, MSD. T. Kawaguchi: Honoraria (self): Chugai. K. Izumi: Full / Part-time employment: Medilead Inc. J. Takehana: Full / Part-time employment: Medilead Inc. Y. Matsumoto: Honoraria (self): Kyowa Kirin; Honoraria (self): Shionogi; Honoraria (self): Terumo; Honoraria (self): Meiji Seika Pharma; Honoraria (self): Hisamitsu Pharmaceutical; Honoraria (self): Eisai; Honoraria (self): Pfizer; Honoraria (self): AstraZeneca; Honoraria (self): Mundipharma; Honoraria (self): Daiichi-Sankyo. All other authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract